Poging GOUD - Vrij

'With an array of partners, we are tackling some of the biggest unmet needs in mental health diseases'

BioSpectrum Asia

|

BioSpectrum Asia Sep 2021

Revealing new answers through precise analysis of the gut microbiome, Australiabased startup Microba Life Sciences is strengthening its presence in the market by partnering with global leaders to turn its discoveries into transformative solutions for medical diagnosis and treatment. To find out more about the solutions being offered by the startup in the microbiome space, BioSpectrum Asia reached out to Dr Luke Holtham Reid, President, Microba Life Sciences, Australia, soon after the World Microbiome Day, celebrated on June 27 every year.

- Dr Manbeena Chawla

'With an array of partners, we are tackling some of the biggest unmet needs in mental health diseases'

Dr Luke Holtham Reid, President, Microba Life Sciences, Australia

What unique initiatives are being taken by the company to connect microbiome with human health? Which are the major therapeutic areas being covered?

Microba Life Sciences is working to make important advancements in medicine by harnessing the gut microbiome as a rich source of novel therapeutics using precision microbiome science. This stems from our proprietary discovery platform that utilises human data and leading informatic approaches to identify promising therapeutic leads. In particular, we have established therapeutic programmes to address unmet clinical needs in our lead programme targeting Inflammatory Bowel Disease (IBD). To support this and our other programmes we have assembled global clinical leaders to guide the pre-clinical and clinical development of these breakthrough therapies. Microba’s IBD therapeutic leads are delivering excellent results in pre-clinical models. The company is now rapidly progressing these into a first-in-human clinical trial. Our rapid progression in therapeutic development is delivering on our mission of using precision microbiome science to enhance human health. We are uniquely placed to discover and develop microbiome-based therapeutics due to our unrivaled MAP technology which provides the most comprehensive and precise measurement of the human gut microbiome.

How is the company contributing to the field of mental health with the help of microbiome research?

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size